Medical Device Clinical Trials: What You Need to Know
"A guide to understanding the growing medical device industry, clinical trial processes, and market trends in South Korea and beyond."
The medical device industry is experiencing rapid growth, outpacing even the pharmaceutical sector. This surge is fueled by constant innovation and the increasing demand for advanced healthcare solutions. As technology advances, so does the need for rigorous testing and evaluation of new medical devices to ensure their safety and effectiveness.
In South Korea, the medical device market is booming, boasting an impressive average annual growth rate of 12.6% between 2006 and 2008. This growth is particularly notable in the production of higher-risk devices (Class 3 and 4), indicating a move towards more sophisticated and technologically advanced medical solutions.
Clinical trials are a critical step in bringing new medical devices to the public. These trials ensure that devices are both safe and effective before they are widely adopted. Recent increases in clinical trial approvals by the Korea Food & Drug Administration (KFDA) signal a positive trend towards scientifically sound and ethically justified research. To meet the growing demand for high-quality trials, the Ministry of Health & Welfare has designated several medical device clinical trial center consortia.
A Field in Growing Demand
Medical device clinical trials have grown into a substantial undertaking within healthcare, driven by the rising burden of chronic disease and an expanding pipeline of new technologies. Current evidence on the exact size and trajectory of this market is limited and varies by source, so precise figures should be treated cautiously. What is broadly agreed, however, is that regulatory expectations in major markets are tightening and that device sponsors must generate rigorous human-subject evidence to reach patients.
Guidance, GCP and the Limits of the Evidence Hierarchy
The core framework for conducting device trials rests on FDA guidance documents, which represent the agency's current thinking on good clinical practice and human subject protection. In practice, device studies increasingly follow Good Clinical Practice under ISO 14155:2026 alongside the revised ICH E6(R3) standard, covering sponsor duties, informed consent, safety reporting and audit readiness. A persistent limitation, though, is that devices do not sit neatly inside the classical evidence hierarchy: as a Springer article notes, compared with pharmaceuticals there is no equally rigorous formal regulation for demonstrating benefits and excluding harms, and the device industry argues that randomised clinical trials cannot simply be applied to device evaluation. To address such gaps, initiatives including the Clinical Trials Transformation Initiative (CTTI) and the Medical Device Innovation Consortium (MDIC) have proposed structured approaches that define criteria for data quality, governance mechanisms and the validity of analytical methods.
From Biblical Legumes to the 1946 Streptomycin Trial
The history of clinical research stretches back further than many realize: accounts trace a lineage from the first recorded trial of legumes in biblical times through to the first randomized controlled trial of streptomycin in 1946, according to a PMC review of the field's evolution. The middle of that story is anchored by Scottish surgeon James Lind's mid-1700s scurvy study conducted on sailors, which is widely cited as the first recorded clinical trial. Later milestones include the ethics and protections formalized after the Nuremberg era and the eventual consolidation of standards into ICH GCP. Recent chronicles, including CASRAI's guide to trial milestones, carry the narrative forward to modern decentralized trials, noting why this history matters for today's research administrators.
Navigating the Medical Device Approval Process
Unlike pharmaceuticals, medical devices often have shorter lifecycles, allowing for quicker market entry and easier adaptation to user needs. This rapid innovation, however, necessitates careful evaluation and oversight to protect patient safety. In South Korea, medical devices are classified into four classes based on their potential risk to patients.
- Class 1: Devices with minimal potential harm (e.g., mechanical stethoscopes, mercury thermometers).
- Class 2: Devices with low potential harm (e.g., electronic stethoscopes, CT systems).
- Class 3: Devices with moderate potential harm (e.g., hemodialysis systems, peripheral vascular prostheses).
- Class 4: Devices with high potential harm (e.g., central vascular prostheses, biodegradable orthopedic fixation plates).
Mapping the Device Trial Evidence Base
Recent scrutiny has focused on what the published record of medical device clinical investigations actually contains. A scoping review, published in Trials in March 2025 and also available on PMC, was prompted partly by enhanced European regulatory requirements for clinical investigations and the perceived need for higher-level, publicly available evidence. The review set out to map published device investigations by device type and clinical specialty and to summarize key trial design aspects. Alongside such analyses, aggregators like Springer's Clinical Trials subject feed and news outlets such as infomeddnews continue to surface the newest papers, opinions and industry developments in medical device trials.
When Trials Fall Short of the Ideal
No clinical trial program is guaranteed to succeed, and device studies are no exception in facing recruitment difficulties, protocol deviations, interim findings that reverse expectations and trials that fail to reach their endpoints. Because device development is tightly linked to fast-moving design iterations, some investigators contend that conventional trial timelines are a poor match for the product lifecycle. The available material offers little settled quantitative evidence on failure rates, so these points should be read as general observations rather than established figures. What is clear is that careful planning and disciplined execution remain decisive in whether a device study delivers data that regulators and clinicians can rely on.
Device Trials vs. Drug Trials
Medical device clinical trials share many features with pharmaceutical trials but differ in important ways in how they are designed and carried out — and in some cases, as an industry overview from McNeil notes, a clinical trial may not even be required for a device. In both the US and the EU, trials are mandated for certain risk classes, with the EU requiring them for all Class III and Class IIb implantable devices, and sponsors must complete preclinical safety testing before any human study begins. Subsequent blind selections of successive, often iterative, device versions make masking and sham controls more complex than in drug studies, a theme OpenClinica explores in its list of eight ways the two trial types diverge. Commercially, the field is substantial: a 2026 research report put the medical device clinical trials market at over $25 billion, with growth tied to rising chronic diseases, wearable technology and decentralized trials.
The Future of Medical Device Clinical Trials
The medical device industry in South Korea is poised for continued growth, driven by technological advancements and increasing healthcare demands. As the industry matures, clinical trials will play an increasingly important role in ensuring the safety and effectiveness of new devices.
Where the Specialists Weigh In
A dedicated commentary and analysis ecosystem now surrounds the device trial field. The MEDLINE-indexed journal Expert Review of Medical Devices, for example, exists specifically to provide commentary, analysis and debate for professionals involved in the research, development, testing and clinical use of devices. At the trade level, Medical Economics operates a medical device and technology hub covering FDA clearances, emerging tech, funding and industry trends for physicians, investors and healthcare executives. Quantitative observers have also begun dissecting the public record: a 2026 teardown of the ClinicalTrials.gov database examined phase NA dominance, results-reporting compliance, sponsor classes and decadal growth trends in device trials. Market intelligence firms, including Grand View Research's medical devices team, meanwhile publish multi-year market reports projecting the sector's trajectory to 2030.
What Comes Next Is Being Written Now
The direction of device trials is generally expected to keep moving toward more connected, evidence-rich and patient-centered designs, though specific forecasts are not available and should not be overstated. Decentralized and wearable-enabled approaches are frequently cited as ways to capture real-world performance beyond the clinic, and analytics tools are seen as a means of compressing study timelines. Adoption of these methods is likely to be uneven across device classes and regions, shaped by regulatory readiness as much as by technology. Ultimately, how quickly — and how convincingly — these frontiers mature will depend on the willingness of sponsors and regulators to pilot and validate them at scale.
A Global Patchwork of Rules
Medical device trials operate against a complex global regulatory backdrop that directly affects innovation. A ResearchGate analysis of global regulatory challenges concludes that evolving regulations restrict market access for new technologies and can slow innovation cycles. The picture varies by jurisdiction: in Japan, for example, sponsor-initiated global device trials are typically conducted under Articles 80-2 and 3 of the Pharmaceutical and Medical Device Act, as an analysis in ScienceDirect explains. In the United States, a ScienceDirect assessment of the device development ecosystem concludes that major changes in device translational research have improved the research climate, while goals remain — including increased training and education for constituencies working in device development and regulation as part of a continuous healthcare learning system.
Trials in Service of Patients
Behind the protocols, dossiers and compliance checklists, medical device trials exist to answer a basic question: does this technology make life better and safer for the people who use it? Each study enrolls patients who, by participating, help determine whether a device will reach the clinic, and their experience shapes both the quality of the data and the credibility of the results. Regulators, clinicians and sponsors ultimately weigh the same human stakes when deciding whether evidence is strong enough to justify market approval. For the patients who later receive these devices, the rigor of that human-subject evidence is the difference between an informed and a speculative introduction of new technology.
Compared to the well-established pharmaceutical clinical trial landscape, medical device trials are still evolving. However, South Korea's strong IT infrastructure and growing investment in healthcare technology provide a solid foundation for future growth in this area.
To foster continued progress, collaboration between government, academia, industry, and healthcare providers is essential. By working together, these stakeholders can create a supportive ecosystem for innovation and ensure that patients have access to safe and effective medical devices.